NEJM 20 Feb 2014 Vol 370 699 This week, the NEJM is big on bevacizumab. Amongst the crowd of mabs, this is one of the best known: Avastin is a humanized monoclonal antibody directed against vascular endothelial growth factor-A which has been on the market since 2004. It has had its ups and downs, and […]
Richard Lehman’s journal review—24 February 2014
